Article
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
Antimicrobial agents and chemotherapy - 1 Jan 2015
Ottosen Søren, Parsley Todd B, Yang Lu, Zeh Karin, van Doorn Leen-Jan, van der Veer Eva, Raney Anneke K, Hodges Michael R, Patick Amy K
Abstract excerpt
Miravirsen is a β-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). Miravirsen demonstrated antiviral activity against hepatitis C virus (HCV) genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 μM. No cytotoxicity was observed up to the highest concentration tested (>320 μM) in different cell culture models,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.